MRI in Diagnosing Solid Tumors of the Eye and Orbit

  • STATUS
    Recruiting
  • End date
    Dec 31, 2024
  • participants needed
    160
  • sponsor
    Ohio State University Comprehensive Cancer Center
Send
Updated on 28 April 2022
See if I qualify

Summary

This study is being done due to a new imaging method that may help others in the future to improve evaluation of diseases in the eye and eye socket and to help make a decision concerning best treatment of the disease. Previous studies suggests that dynamic contrast enhanced MRI is ideally suited to show small structures in the eye and eye socket as well as to provide information about the eye socket such as blood circulation. This research may also provide information about the likelihood of the tumor spreading from the eye into other organs as well as correlate the study images with all other clinical imaging

Description

PRIMARY OBJECTIVES:

I. To determine the feasibility of DCE-MRI (dynamic contrast enhanced magnetic resonance imaging) as non-invasive imaging tool to image contrast enhancement in ocular and orbital tumors.

II. To compare contrast enhancement and its distribution within orbital tissue. III. To assess potential differences in contrast enhancement which help to characterize malignant lesions as well as discriminate these from benign tissue.

IV. To compare image characteristics between clinical high field end ex-vivo ultra high field magnetic resonance (MR) imaging.

V. To correlate imaging findings with obtained histology by comparing contrast enhancement parameters, e.g. maximum signal intensity, to histology characteristics, e.g. vascular density.

OUTLINE

Patients undergo DCE-MRI.

After completion of study treatment, patients are followed up every 6 months for up to 5 years.

Details
Condition Eye Cancer
Treatment dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), Dynamic contrast-enhanced MRI
Clinical Study IdentifierNCT01653080
SponsorOhio State University Comprehensive Cancer Center
Last Modified on28 April 2022

Eligibility

 Yes No Not Sure

Inclusion Criteria

The patient has an orbital mass which needs further diagnostic evaluation before treatment or for monitoring
Able to give informed consent
Return for follow-up visits

Exclusion Criteria

Patients with a lesion < 2 mm
The patient should not participate in this study is any of the following applies to the patient: the patients has a pacemaker, metallic cardiac valve(s), magnetic material such as surgical clips, implanted electronic infusion pumps or any other condition that would interfere with the MRI, the patient has a stent somewhere in the body, the patient has a history of allergic reaction to any metals, contrast agents, x-ray dyes, the patient has claustrophobia
Patients cannot be pregnant and prisoners will not be considered for the study
Exposure to gadolinium-based contrast agents increases the risk for nephrogenic systemic fibrosis (NSF) in patients with acute or severe renal dysfunction; therefore, patients with the following conditions are excluded from the study
Acute or chronic severe renal insufficiency (glomerular filtration rate < 30 mL/min/1.73 m^2)
Acute renal dysfunction due to the hepato-renal syndrome or in the perioperative liver transplantation period
In order to identify subjects at risk for the development of NSF, the American College
patients
of Radiology (<http://acr.org>) recommends obtaining a medical history and a
Renal disease (including solitary kidney, renal transplant, renal tumor)
glomerular filtration rate (GFR) assessment within six weeks of MR imaging in
Age > 60
the following
History of hypertension
History of diabetes
History of severe hepatic disease/liver transplant/pending liver transplant
All subjects providing written informed consent will complete the subject history and
screening form prior to MR imaging; the form will be reviewed to determine
whether the subject is at risk as defined above and the availability of an
estimated glomerular filtration rate (eGFR) within six weeks of anticipated MR
imaging; an eGFR result greater than six weeks prior to the MRI imaging date
will be repeated and evaluated for renal function; subjects with an eGFR of <
mL/min/1.73 m^2 will be excluded from the study
Clear my responses
Read more

How to participate?

Step 1 Connect with a study center
What happens next?
  • You can expect the study team to contact you via email or phone in the next few days.
  • Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Investigator Avatar

Primary Contact

site

0/250

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Sign up as volunteer

user name
Edit Delete

Added by • 

 • 

Private

Edit Delete

Reply by • • Private
Edit Delete

Lorem ipsum dolor sit amet consectetur, adipisicing elit. Ipsa vel nobis alias. Quae eveniet velit voluptate quo doloribus maxime et dicta in sequi, corporis quod. Ea, dolor eius? Dolore, vel!

  The passcode will expire in None.

No annotations made yet

Add a private note
  • abc Select a piece of text from the left.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.
Add a private note